---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-245807"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2023-09-28T23:59:59+00:00"
generated_at: "2026-06-10T07:44:04.887933+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Benitec Biopharma regains Nasdaq compliance with $28.6M equity offering

## Summary
- Regained compliance with Nasdaq minimum stockholders' equity rule via $28.6M net proceeds from August 2023 offering.
- As of June 30, 2023, stockholders' equity was below $2.5M requirement; offering resolved deficiency.
- Offering included 875,949 common shares, 15,126,226 pre-funded warrants, and 16,002,175 common warrants at $1.93 per unit.
- Nasdaq will continue to monitor compliance; non-compliance at next report could lead to delisting.

## SEC filing metadata
- accession: 0001193125-23-245807
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2023-09-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312523245807/0001193125-23-245807-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312523245807/d512438d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-245807
- JSON: https://secwatch.observer/filing/0001193125-23-245807.json
- Plain text: https://secwatch.observer/filing/0001193125-23-245807.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.